Companies terminate merger agreement following FDA's Aug. 23 inspection report finding inconsistencies in Gliatech's study data for the anti-adhesion gel product Adcon-L. Guilford said Aug. 28 that "in light of Gliatech's need to focus on certain of its ongoing regulatory and product development matters," the parties mutually agreed to end the proposed merger. The $207 mil. merger was announced May 30 (1"The Pink Sheet" June 5, p. 17)
You may also be interested in...
Guilford Pharmaceuticals has gained rights to Gliatech's adult attention deficit hyperactivity disorder agent Perceptin as part of a merger agreement announced by the companies May 30.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials